We recently discovered apoE as a regulator of cav-1 distribution in adipocytes. ApoE colocalizes with cav-1 in adipocytes, and an N-terminal portion of apoE enriched in aromatic amino acids displays affinity for the cav-1 scaffolding domain. 16 The cav-1 scaffolding domain is also the proposed site for cav-1 interaction with eNOS. Endothelial cells express high levels of cav-1 but do not express apoE. In view of the importance of macrophage-derived apoE for preserving vessel wall homeostasis, 4-6 the previously demonstrated Abstract-Apolipoprotein E (apoE) is widely expressed in mammalian tissues, and one of the important tissue-specific effects is the atheroprotection ascribed to macrophage-derived apoE in the arterial wall. However, underlying mechanisms are not well understood. In this study, using subcellular fractionation, confocal microscopy, and coimmunoprecipitation, we demonstrated that macrophage-derived apoE is internalized by endothelial cells and impacts the subcellular distribution/interaction of caveolin 1 (cav-1) and endothelial NO synthase (eNOS). The addition of apoE disrupts the heteromeric complex formed between cav-1 and eNOS, and increases NO production. Sterol and oxysterol enhance endothelial cav-1/eNOS interaction and suppress NO production, but these effects are reversed by apoE. Silencing endothelial cav-1 attenuates apoE-induced NO production, establishing the importance of the cav-1-eNOS interaction for the increment in endothelial NO produced by apoE. Consistent with these observations, macrophage-derived apoE significantly improves vasodilation to acetylcholine in resistance arteries isolated from adipose tissue of obese humans. We conclude that macrophage-derived apoE enhances endothelial NO production by disrupting the inhibitory interaction of eNOS with cav-1. These results establish a novel mechanism by which apoE modulates endothelial cell function. 
A polipoprotein E (apoE), primarily produced in hepatocytes, circulates as a surface component of human very low-density lipoprotein and high-density lipoprotein and plays a major role in directing the systemic metabolism of these particles. However, apoE is also produced at a high level in extrahepatic tissues, for example, by macrophages and adipocytes. [1] [2] [3] Macrophage-derived apoE, in particular, has been shown to be important in the vessel wall, where it contributes to atheroprotection. [4] [5] [6] Vessel wall accumulation of monocyte-derived macrophages occurs early in atherogenesis, and the ability to modulate apoE concentration in response to local tissuespecific stimuli is likely important for vessel wall injury and physiological stress. Production and secretion of apoE by macrophages is substantially augmented by sterols and oxysterols. 7, 8 This increase in macrophage-derived apoE could be viewed as a protective response to the vessel wall injury caused by these agents.
Endothelial dysfunction, as manifested by impaired endothelium-dependent vasodilation, is well established as a marker of atherosclerosis, hypertension, and future cardiovascular events. [9] [10] [11] Impaired production of NO by endothelial cells underlies impaired endothelium-dependent vasodilation, and factors that regulate such production have, therefore, been the target of intensive investigation. For example, apoE derived from transfected Chinese hamster ovary cells suppresses the activation of endothelial cells, most likely by stimulating activity of endothelial NO synthase (eNOS). 12 An inhibitory interaction between the endothelial cell caveolin 1 (cav-1) and eNOS is thought to be an important factor regulating endothelial NO production, and stimuli that facilitate this interaction are associated with accelerated vascular disease. 13, 14 For example, hyperlipidemia enhances the cav-1-eNOS interaction and reduces endothelial NO production. favorable effect of exogenous apoE for suppressing endothelial cell activation, 12 and the proximity of macrophages to endothelial cells in the injured vessel wall, we examined whether macrophage-derived apoE is taken up and retained by endothelial cells, whether internalized apoE impacts endothelial cell cav-1 subcellular distribution, and what impact macrophage-derived apoE would have on the cav-1-eNOS association. We further explored the functional relevance of macrophage-derived apoE on NO production in human endothelial cells and on NO-dependent vasodilation of resistance arteries isolated from humans.
Methods
Please see the online-only Data Supplement for the expanded Methods section.
Sodium Carbonate Extraction and Sucrose Gradient Isolation of Caveolae
The procedure to isolate human umbilical vein endothelial cell (HUVEC) caveolae was based on the detergent-free protocol, as described previously.
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NO Production Measurement and Cav-1 Knockdown
The membrane-permeable fluorescent indicator diacetate (4-amino-5-methylamino-2′,7′-difluorofluorescein) diacetate (DAF-FM) was used as a probe to measure NO production. After removing the medium, the endothelial cells were loaded with 10 µmol/L of DAF-FM diacetate in M199 without phenol red for 30 minutes at 37°C and washed 3 times. After adding apoE-conditioned medium, intracellular NO change was measured using a Synergy HT microplate reader (BIO-TEK) with excitation and emission wavelength of 485 nmol/L and 528 nmol/L for every 30 minutes at 37°C or as indicated.
Validated SureSilencing human cav-1 short hairpin RNA and control plasmids were purchased from SA Biosciences (Frederick, MD). Early passages of HUVECs were transiently transfected with short hairpin RNA using TransPass HUVEC Transfection Reagent (New England BioLabs, Ipswich, MA) following the manufacturer's protocols. Seventy-two hours posttransfection, the combined RNA/ protein isolation was performed using the NucleoSpin RNA/Protein kit (Macherey-Nagel) according to the manufacturer's instructions. The knockdown of cav-1 was measured by RT-PCR and Western blot.
Study Subjects
Visceral fat was obtained from subjects (woman; BMI 48±12 kg/ m 2 ; n=12) undergoing bariatric surgery (Table S1 , available in the online-only Data Supplement). Subjects with medical conditions were excluded. The study was approved by the University of Illinois Institutional Review Board, and all of the subjects gave written informed consent. Resistance arteries were cleaned of fat and connective tissue and prepared for measurement of vessel diameter, as described previously. 17, 18 Male apoE knockout and age-matched C57BL/6J mice were purchased from Jackson Laboratory. All of the animal protocols were approved by the institutional animal care and use committee of the University of Illinois at Chicago.
Statistical Analysis
Data are expressed as mean±SD. Dilation to acetylcholine is expressed as a percentage of maximum response to papaverine (10 −4 m). Vasodilator responses were assessed with a repeated-measured ANOVA. Comparisons were performed using the 1-way ANOVA. Differences were judged to be significant at the level of P<0.05.
Results
Macrophage-Derived ApoE Is Taken Up and Retained by Endothelial Cells and Modulates the Subcellular Distribution of Cav-1 and eNOS
Using RT-PCR and Western blot, no endogenous apoE was detected in HUVECs or mouse endothelial cells (data not shown). Although apoE circulates at ≈5 mg/dL in the plasma, macrophage-derived apoE may be most important for defending normal vessel wall homeostasis. [4] [5] [6] We used the J774 macrophage cell line (which does not produce endogenous apoE) and transfected it to constitutively secrete a physiological level of human apoE3 (J774E cells). As a control, we used J774 cells transfected with a G418 resistance construct only (J774C cells). After a 2-hour incubation in J774E-conditioned medium, intact apoE was easily detectable in the endothelial monolayer by Western blot (data not shown).
To evaluate the subcellular distribution of the exogenously added apoE in endothelial cells, and if this addition affected endothelial cav-1 and eNOS subcellular distribution, we next performed sucrose gradient fractionation ( Figure 1 ). After incubation in J774C-CM ( Figure 1A ) without added cholesterol (CH; Figure 1A , top), cav-1 was distributed in lighterdensity membrane fractions 4 and 5, as well as in denser fractions 8 through 11. eNOS was distributed throughout the gradient. The addition of CH to cells incubated in J774C-CM led to enrichment of cav-1 in the lighter density membrane fractions 3 through 5 and shifted eNOS into the lighter-density membrane fractions containing cav-1, thus leading to greater colocalization of these proteins in the light-membrane caveolar fraction. After incubation in J774E-CM ( Figure 1B ), apoE was detected in high-density cell fractions, and both eNOS and cav-1 appear shifted out of lighter-density membrane fractions and into higher density cell fractions. J774E-CM also suppressed the shift of cav-1 and eNOS into lighter density membrane fractions that was produced by CH. Figure  1C quantitates these observations by presenting the ratio of cav-1:eNOS in low-density membrane to high density membrane fractions. In both the absence and presence of CH, apoE reduced the colocalization of eNOS with cav-1 in light-density caveolar fractions.
We next used confocal microscopy to evaluate the subcellular localization of apoE, endogenous cav-1, and eNOS in endothelial cells ( Figure S1 , available in the online-only Data Supplement). In the top panels of Figure S1A , endothelial cells stained for cav-1 and eNOS after incubation in J774C-CM are shown. Cav-1 and eNOS are detected throughout cells, and the only colocalization is observed in the perinuclear region. Consistent with the results of Figure  1A , there is significant new colocalization at the endothelial cell plasma membrane after incubation with CH. In the bottom panels, after incubation in J774E-CM, there continues to be a small amount of colocalization of cav-1 and eNOS in the perinuclear region, but the colocalization at the plasma membrane after incubation in CH is suppressed, consistent with the results of the subcellular fractionation. The degree of colocalization of Cav-1 and eNOS normalized to that present in J774C-CM without CH is quantitated at the bottom panel Figure S1A . In Figure S1B , staining for apoE and cav-1 shows that apoE distribution is largely intracellular and that apoE suppresses the ability of CH to shift cav-1 to the plasma membrane. Incubation with CH produces a substantial amount of intracellular colocalization of cav-1 and apoE.
ApoE Disrupts the Interaction of Cav-1 and eNOS
The above results suggest that apoE can disrupt the interaction between cav-1 and eNOS. The change in the colocalization of eNOS and cav-1 in response to incubation with macrophagederived apoE was quantitatively evaluated using coimmunoprecipitation (Figure 2 ). For these experiments, endothelial cells were incubated in J774C or J774E-CM with or without added CH, as shown. After immunoprecipitation with the cav-1 antibody, the total amount of cav-1 was not changed by the different incubation conditions. CH increased coimmunoprecipitation of eNOS with cav-1×1.7-fold in J774C-CM ( Figure 2B ). However, the amount of eNOS coimmunoprecipitated with cav-1 was significantly reduced after incubation in J774E-CM in both the absence and presence of CH. Using apoE antibody ( Figure 2C ) led to coimmunoprecipitation of cav-1; however, no eNOS was detected in the complex. This result indicates that the cav-1 associated with eNOS is distinct from the cav-1 associated with apoE.
ApoE Regulates Endothelial Cell NO Production in a Cav1-Dependent Manner
We next determined whether apoE modulates NO production in HUVECs. As shown in Figure 3A , the addition of J774E Figure 3B ) led to elimination of the difference in NO production by J774C compared with J774E-CM ( Figure 3C ), confirming the importance of the Cav-1-eNOS interaction for the apoE effect. The addition of either CH or 7-ketocholesterol inhibited NO production in endothelial cells incubated with J774C-CM ( Figure 3D) . However, the addition of J774E-CM completely reversed this inhibition. In Figure 3E , using the same incubation conditions described in Figure 3D , the amount of eNOS coimmunoprecipitated with cav-1 is increased by incubations with CH or 7-ketocholesterol. However, the amount of eNOS coimmunoprecipitated with cav-1 is markedly decreased by apoE both in the absence or presence of sterol. Total cellular cav-1 and eNOS do not change. We next evaluated the effect of apoE on acetylcholine-stimulated NO production ( Figure 3F ). Acetylcholine significantly stimulated NO production under all of the incubation conditions studied ( Figure 3F , gray bars versus black bars). However, after the addition of CH or 7-ketocholesterol in J774C-CM, both unstimulated ( Figure 3F , black bars) and stimulated ( Figure 3F , gray bars) NO productions are decreased. The addition of apoE to the endothelial cells, however, completely restores endothelial NO production in the presence of sterols.
ApoE Is Detectable in the Endothelium of Intact Vessels In Vivo
To confirm that apoE could be localized to endothelial cells in vivo, sections of aorta and heart were prepared from C57Bl/6 mice or apoE knockout mice ( Figure S2 ) and stained for apoE and CD31 (an endothelial cell-specific marker). ApoE was detected only in wild-type mice. In both aortic and intra myocardial vessels, apoE and CD31 colocalization were easily detectable ( Figure S2 ).
ApoE Enhances Acetylcholine-Mediated Dilation of Intact Human Vessels
Increased endothelial NO production stimulated by apoE predicts enhanced endothelium-dependent vasodilation by apoE. To confirm this, we measured endothelium-dependent vasodilation in response to acetylcholine with or without perfusion of apoE in human resistance arteries isolated from the adipose tissue of obese humans. For these studies, internal arterial diameters were 124±45 and 67±18 µm before and after endothelin 1 exposure, respectively. As shown in Figure 4A , there was a significant increase in dilation to acetylcholine after exposure to J774E (n=12 subjects; Table S1 ). N G -nitro-L-arginine methyl ester (an inhibitor of eNOS) abolished the vasodilation produced by J774E, indicating that the enhanced dilation depends on eNOS. In contrast, responses to the endothelium-independent vasodilator sodium nitroprusside were similar in both groups, confirming that the improved acetylcholine dilations in the presence of J774E are endothelium dependent and not related to changes in smooth muscle sensitivity to NO ( Figure 4B ). 
Discussion
Our results demonstrate a novel mechanism for the regulation of endothelial cell function by apoE. Macrophagederived apoE is retained intact in endothelial cells where it modulates the subcellular distribution of cav-1, reduces the inhibitory influence of endogenous cav-1 toward eNOS, and increases eNOS-derived NO production. ApoE restores NO generation in sterol-loaded cells and regulates NO-dependent vasodilation in intact human resistance arteries. Although we cannot exclude the possibility that some of the impact of J774E-CM also derives from another factor secreted by macrophages working in concert with apoE, the importance of apoE is demonstrated by its direct association with cav-1 in coimmunoprecipitation experiments, and our recently reported data demonstrating affinity of the N-terminal portion of apoE for cav-1. 16 ApoE knockout mice develop spontaneous hypercholesterolemia, and this, along with other factors, likely contributes to the impaired endothelium-dependent relaxation observed in this model. 19, 20 There are likely multiple mechanisms by which apoE influences endothelial function. For example, apoE promotes reverse CH transport, [21] [22] [23] [24] inhibits endothelial cell activation, 12, 25 and defends against oxidative stress.
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We now demonstrate that apoE suppresses the inhibitory interaction between cav-1 and eNOS and induces NO production by endothelial cells. We further show that apoE restores NO-dependent vasodilation of resistance arteries isolated from the adipose tissue of obese humans, which have been reported to have impaired vasodilation. 27 In the endothelium, cav-1 regulates NO signaling by binding to and inhibiting eNOS activity.
14 Increased cytosolic Ca 2+ /calmodulin or activation of the kinase Akt leads to eNOS activation and its dissociation from cav-1. 28 Direct binding of eNOS to the scaffolding domain of cav-1 is a well-accepted mechanism for downregulating NO production, and stimuli that facilitate this interaction are associated with accelerated vascular dysfunction. 13, 14 Blood vessels from cav-1 knockout mice showed marked enhancement of the relaxation response to acetylcholine, which is reversed by treatment with N G -nitro-l-arginine methyl ester, a specific NO synthase inhibitor, 29, 30 or rescued by reintroduction of cav-1. 31, 32 It is important to note that, whereas an antibody to cav-1 coimmunoprecipitates both eNOS and apoE, an antibody to apoE coimmunoprecipitates only cav-1 but not eNOS. This result suggests that the cav-1 associated with apoE is distinct from the cav-1 associated with eNOS and provides support for a model in which association of apoE with cav-1 competitively reduces the association of cav-1 with eNOS. We have shown previously that an N-terminal domain of apoE enriched in aromatic amino acids displays specific and saturable affinity for the cav-1 scaffolding domain. 16 Therefore, we speculate that apoE association with the cav-1 scaffolding domain could displace eNOS, increase NO production, and thereby modulate vascular tone in a cav-1--dependent manner. ApoE suppression of the inhibitory interaction between cav-1 and eNOS may occur while both remain within plasma membrane domains or by shifting cav-1 to an intracellular location. For example, interrupting this interaction could involve partitioning of cav-1 between low-density and high-density domains of the plasma membrane. [33] [34] [35] [36] Alternatively, the 2 proteins could be separated between plasma membrane and higher-density intracellular membranes. The data in Figure 1 show that apoE does lead to a greater shift of cav-1 than eNOS out of low-density caveolar membrane fractions. The data in Figure S1 are consistent with the interpretation that at least a portion of the shifted cav-1 can be found in an intracellular location. Further evaluation of these 2 possibilities will require additional experimentation.
In summary, our data provide evidence of a novel role for apoE in modulating the cav-1-eNOS interaction in endothelial cells. Modulation of this inhibitory interaction by apoE influences NO production in endothelial cells and likely modulates NO-mediated vasodilation of intact human vessels. The effect of sterol or oxysterol to enhance cav-1/eNOS interaction and to thereby suppress NO production in endothelial cells is reversed by macrophagederived apoE.
Perspectives
The results of the present study provide the first molecular and physiological evidence of a new pathway by which apoE regulates endothelial function. Our findings establish that apoE modulates the cav-1-eNOS interaction and NO production by the endothelium. Taken together these data suggest that the regulation of the cav-1-eNOS interaction by apoE could provide a common mechanism for the pleiotropic effect of this protein across multiple mammalian tissue compartments and provide a novel candidate target pathway for modulating endothelial cell function in vivo.
